ACET Stock Summary and Trading Ideas (Adicet Bio | NASDAQ:ACET)

Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. It is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. The company's main product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, and is being developed for the potential treatment of autoimmune diseases. Additionally, it is pursuing ADI-212, a next-generation gene-edited and armored clinical candidate designed to target prostate-specific membrane antigen (PSMA).

Adicet Bio trades on the NASDAQ stock market under the symbol ACET.

As of November 5, 2026, ACET stock price declined to $2.96 with 235,475 million shares trading.

ACET has a beta of 2.35, meaning it tends to be more sensitive to market movements. ACET has a correlation of 0.14 to the broad based SPY ETF.

ACET has a market cap of $27.71 million. This is considered a Sub-Micro Cap stock.

In the last 3 years, ACET traded as high as $60.32 and as low as $2.87.

The top ETF exchange traded funds that ACET belongs to (by Net Assets): VTI, VXF, IWC, DFMC, DFAS.

ACET has underperformed the market in the last year with a price return of -73.2% while the SPY ETF gained +11.2%. ACET has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -67.9% and -34.1%, respectively, while the SPY returned -3.4% and -3.8%, respectively.

ACET support price is $2.90 and resistance is $3.30 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ACET shares will trade within this expected range on the day.